House Bill 19
116th Congress(2019-2020)
Lower Costs, More Cures Act of 2019
Introduced
Introduced
Introduced in House on Dec 9, 2019
Overview
Text
Introduced
Dec 9, 2019
Latest Action
Dec 19, 2019
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
19
Congress
116
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Sponsorship by Party
Oregon
New York
Alabama
Arkansas
Arkansas
California
California
California
Florida
Florida
Georgia
Illinois
Illinois
Illinois
Illinois
Indiana
Indiana
Indiana
Kansas
Kentucky
Kentucky
Kentucky
Louisiana
Louisiana
Louisiana
Maryland
Michigan
Michigan
Michigan
Minnesota
Minnesota
Mississippi
Missouri
Missouri
Missouri
Nebraska
Nebraska
New Jersey
New York
New York
New York
North Carolina
North Carolina
North Carolina
North Carolina
North Carolina
North Carolina
North Carolina
North Dakota
Oklahoma
Oklahoma
Pennsylvania
Pennsylvania
Pennsylvania
Pennsylvania
Pennsylvania
Pennsylvania
Pennsylvania
Pennsylvania
South Carolina
South Carolina
South Carolina
South Carolina
South Carolina
South Dakota
Tennessee
Tennessee
Tennessee
Tennessee
Virginia
Washington
West Virginia
West Virginia
West Virginia
Wisconsin
Wyoming
No House votes have been held for this bill.
Summary

Lower Costs, More Cures Act of 2019

This bill establishes and modifies several requirements to address prescription drug prices under Medicare, Medicaid, and other programs.

The bill generally

  • limits payment amounts for drugs and biologics under Medicare medical services,
  • reduces cost-sharing under the Medicare prescription drug benefit,
  • modifies certain authorities and requirements under the Medicaid Drug Rebate Program,
  • revises provisions relating to regulatory approval and commercial availability of generics and biosimilars, and
  • establishes several reporting requirements for drug manufacturers with respect to drug prices.
Text (1)
December 9, 2019
Actions (4)
12/19/2019
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
12/10/2019
Referred to the Subcommittee on Health.
12/09/2019
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
12/09/2019
Introduced in House
Public Record
Record Created
Jan 3, 2019 7:01:38 PM
Record Updated
Jul 10, 2021 8:20:53 PM